Prospective European Drug-Induced Liver Injury Network


There is a clear unmet need for a deeper understanding of idiosyncratic drug-induced liver injury (DILI), a multi-layered challenge that spans the life of the drug from pre-clinical development to clinical trials and post-marketing.

The objectives of the PRO-EURO-DILI-NET Cost Action are to create a unique, co-operative, interdisciplinary European-based DILI network of stakeholders to co-ordinate efforts in DILI, to facilitate bi-directional exchange of discovered knowledge and generated hypotheses among different disciplines, and to promote clinically impactful knowledge discovery and its translation into clinical practice.

This Action will:

(a) harmonize efforts for in-depth DILI phenotyping and bio-sample repository and coordinate pre-funded database/repository studies to aggregate a large number of DILI cases in a standardized manner (WG1).

(b) Establish a strategy for development, validation and performance of DILI novel biomarkers and explore multifactorial DILI risk modifiers in clinical data sets using novel approaches for future precision medicine (WG2).

(c) Facilitate clinically impactful knowledge discovery by introducing biological variations and the complexity (i.e., multi-cellular/multiorgan systems) into toxicological experiments to assess hepatotoxicity to guide future drug safety testing (WG3).

(d) Define criteria and establish endpoints to measure efficacy on novel interventions in DILI (WG4).

(e) Draft policy recommendations about near-patient testing tools.

The network will promote and coordinate a highly translational and innovative research program in Europe and beyond with the ultimate goal to pre-empt and prevent DILI, develop innovative therapeutic approaches that could improve clinical outcomes and enhance public awareness, while developing a forum for knowledge exchange and training of young European researches.

For futher details link to COST CA-17112 in https://www.cost.eu/actions/CA17112




Our DHILI Consortium has been added to the EASL website. Becoming an official EASL Consortium brings us the possibility to…

European Commission’s Open Access publishing platform for research stemming from Horizon Europe
European Commission’s Open Access publishing platform for research stemming from Horizon Europe

  COST Actions can now submit their scientific publications directly to Open Research Europe (ORE), the European Commission’s Open Access publishing platform for…

Launch of Personalised Prescribing report 2022
Launch of Personalised Prescribing report 2022

Prof Guruprasad Aithal, Vice Chair of the COST Action CA17112 who presented evidence to the working party said- ‘There are…